BRIEF published on 01/08/2025 at 14:35, 1 year 5 months ago Health Canada Approves Formycon's Biosimilar FYB202/Otulfi® Healthcare Costs Biosimilar Formycon Ustekinumab Canada Approval
BRIEF published on 01/08/2025 at 14:35, 1 year 5 months ago Santé Canada approuve le médicament biosimilaire FYB202/Otulfi® de Formycon Formycon Ustekinumab Coûts Des Soins De Santé Biosimilaire Approbation Du Canada
PRESS RELEASE published on 01/08/2025 at 14:30, 1 year 5 months ago Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Formycon and Fresenius Kabi Canada obtain Health Canada's approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Health Canada Approval Biosimilar Formycon Stelara Fresenius Kabi Canada
BRIEF published on 12/11/2024 at 16:31, 1 year 6 months ago Formycon AG Maintains Strong Growth Prospects Amidst Challenging Market Conditions FDA Approval Revenue Decline Formycon AG Biosimilars Stelara Launch
BRIEF published on 12/11/2024 at 16:31, 1 year 6 months ago Formycon AG maintient de solides perspectives de croissance dans un contexte de marché difficile Formycon AG Baisse Des Revenus Approbation De La FDA Biosimilaires Lancement De Stelara
PRESS RELEASE published on 12/11/2024 at 16:26, 1 year 6 months ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research publishes update on Formycon AG with BUY rating and EUR 82.00 price target, highlighting decline in revenue and upcoming biosimilar launches First Berlin Equity Research BUY Rating Formycon AG EUR 82.00 Price Target Biosimilar Launches
BRIEF published on 12/09/2024 at 06:35, 1 year 6 months ago MS Pharma to Commercialize FYB202 in MENA MENA Region Formycon AG Biosimilars MS Pharma FYB202
BRIEF published on 12/09/2024 at 06:35, 1 year 6 months ago MS Pharma va commercialiser FYB202 dans la région MENA Formycon AG MS Pharma Région MENA FYB202 Biosimilaires
PRESS RELEASE published on 12/09/2024 at 06:30, 1 year 6 months ago MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Formycon AG and MS Pharma sign licensing and supply agreement for the commercialization of FYB202/ustekinumab biosimilar in MENA region, expanding patient access to vital treatments MENA Region Formycon AG MS Pharma FYB202 Ustekinumab
BRIEF published on 12/05/2024 at 13:00, 1 year 6 months ago Formycon Joins the SDAX of the German Stock Exchange Market Strategy Biosimilars SDAX Formycon German Stock Exchange
Published on 06/27/2026 at 16:50, 1 day 14 hours ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 2 days 5 hours ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 2 days 7 hours ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 2 days 8 hours ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 2 days 8 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/29/2026 at 03:05, 3 hours 56 minutes ago Monport Launches Mid-Year Sale Across Europe with Discount on Laser Engravers and Exclusive Free Gifts
Published on 06/29/2026 at 02:30, 4 hours 31 minutes ago Growing Demand for Color Metal Engraving Drives Interest in Advanced Fiber Laser Technology
Published on 06/29/2026 at 02:15, 4 hours 46 minutes ago A 'founding father of fitness' - Les Mills Snr 1934 - 2026
Published on 06/29/2026 at 02:05, 4 hours 56 minutes ago WIRobotics Begins Building a Physical AI Development Ecosystem: The First Technology Release Features the ALLEX Simulation Model
Published on 06/28/2026 at 20:00, 11 hours 1 minute ago CPI Property Group – Successful Hybrid Tender and New Issue
